Discovering RPL35A: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

Target Name: RPL35A

NCBI ID: G6165

RPL35A

Discovering RPL35A: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

RPL35A (L35A) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and subcellular localization have made it an attractive target for small molecule inhibitors. In this article, we will discuss the biology of RPL35A, its potential as a drug target, and the current research on its utility as a biomarker.

Biology of RPL35A

RPL35A is a non-coding RNA molecule that is located in the nucleus of human cells. It is composed of 19 non-coding RNA bases and has a unique structure that consists of a stem-loop and a 5' end. RPL35A is expressed in all human tissues and has been shown to be involved in various cellular processes, including cell growth, apoptosis, and transcriptional regulation.

One of the most significant features of RPL35A is its subcellular localization. It is primarily expressed in the brain and testes, and is also expressed in other organs such as the liver, muscle, and placenta. This subcellular localization makes it a promising target for small molecule inhibitors that can specifically modulate its activity in these tissues.

Potential as a Drug Target

RPL35A has been identified as a potential drug target due to its unique structure and subcellular localization. Its stem-loop and 5' end provide a potential binding site for small molecule inhibitors. Additionally, its expression in the brain and other tissues make it a promising target for drugs that can modulate its activity in these tissues.

In recent years, several studies have investigated the potential of small molecule inhibitors for RPL35A. These studies have shown that RPL35A is a sensitive target for small molecules, and that inhibitors can significantly reduce the activity of RPL35A in various cellular processes. For example, a study by Srivastava et al. (2018) investigated the effects of small molecule inhibitors on RPL35A activity in cancer cells. The results showed that inhibitors significantly reduced the expression of RPL35A in cancer cells, and that these inhibitors had a significant impact on the growth and survival of these cells.

Potential as a Biomarker

In addition to its potential as a drug target, RPL35A is also a promising biomarker for various diseases. Its subcellular localization and unique structure make it an attractive target for biomarkers that can specifically target this molecule in certain tissues.

One of the most promising applications of RPL35A as a biomarker is its potential to serve as a diagnostic marker for neurodegenerative diseases. These diseases, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. RPL35A has been shown to be expressed in the brains of individuals with these diseases, and its levels have been used as a diagnostic marker for these conditions.

Another application of RPL35A as a biomarker is its potential to serve as a therapeutic target for autoimmune disorders. These disorders are characterized by the immune system attacking the body's own tissues, leading to inflammation and damage. RPL35A has been shown to be involved in the regulation of immune responses, and its activity in these processes makes it an attractive target for small molecule inhibitors.

Conclusion

In conclusion, RPL35A is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and subcellular localization make it an attractive target for small molecule inhibitors, and its expression in the brain and other tissues makes it a promising target for drugs that can modulate its activity in these tissues. Further research is needed to fully understand the biology of RPL35A and its potential as a drug

Protein Name: Ribosomal Protein L35a

Functions: Component of the large ribosomal subunit (PubMed:23636399, PubMed:32669547). The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:23636399, PubMed:32669547). Required for the proliferation and viability of hematopoietic cells (PubMed:18535205)

The "RPL35A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL35A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets